Florida's Limits on Schedule II Prescribing by Telehealth

Florida is one of the few states that writes a Schedule II rule directly into its telehealth statute. Fla. Stat. § 456.47(2)(c) reads: "A telehealth provider may not use telehealth to prescribe a controlled substance listed in Schedule II of s. 893.03 unless the controlled substance is prescribed for" one of four purposes. It applies to every telehealth provider treating a patient located in Florida, whether Florida-licensed, compact-licensed or registered from out of state.

What are the four exceptions?

1. "The treatment of a psychiatric disorder."
2. "Inpatient treatment at a hospital licensed under chapter 395."
3. "The treatment of a patient receiving hospice services as defined in s. 400.601."
4. "The treatment of a resident of a nursing home facility as defined in s. 400.021."

Everything else is out. A Schedule II opioid for chronic pain, prescribed by video to a patient at home, is not permitted by telehealth in Florida no matter what DEA's temporary rule allows. Neither is a Schedule II drug for a non-psychiatric indication such as narcolepsy, unless the patient is a hospital inpatient, in hospice or in a nursing home.

Does ADHD count as a psychiatric disorder?

The statute does not define "psychiatric disorder." Virtual ADHD practices treating Florida patients rely on the exception, on the footing that ADHD is a diagnosis in the DSM, and we are not aware of a published Board of Medicine ruling to the contrary. It is still an interpretation, not a statutory list. Write it down: the diagnosis, the criteria used, and the clinician's documentation that the stimulant treats that psychiatric disorder. Take the reading to Florida counsel. Our broader post on ADHD stimulants by telehealth covers the federal side.

What other Florida rules apply to a Schedule II prescription?

Fitting an exception gets you past § 456.47. It does not get you past the rest of Florida law:

• Acute pain opioid supply. For acute pain, a Schedule II opioid prescription may not exceed a 3-day supply, or up to 7 days if the prescriber judges it medically necessary, writes "ACUTE PAIN EXCEPTION" on the prescription and documents the reason. Non-acute pain prescriptions must be marked "NONACUTE PAIN" (Fla. Stat. § 456.44(5)).
• Chronic nonmalignant pain. Prescribers of Schedule II, III or IV drugs for chronic nonmalignant pain must designate themselves as controlled substance prescribing practitioners, and must do a complete history and "a physical examination" before beginning treatment, then see the patient at intervals of no more than three months (§ 456.44(2)-(3)). Even where a pain drug is Schedule III or IV and therefore outside § 456.47(2)(c), the physical examination requirement makes a telehealth-only pain practice hard to defend.
• NP and PA seven-day caps. The APRN controlled substance formulary must limit Schedule II prescribing to a 7-day supply, except psychiatric medications prescribed by psychiatric nurses as defined in § 394.455 (Fla. Stat. § 464.012(6)(a)). The PA formulary must likewise limit Schedule II to a 7-day supply, with a 14-day limit for certain pediatric psychiatric prescriptions under specified supervision (Fla. Stat. § 458.347). A family NP prescribing a 30-day stimulant supply to a Florida patient has a scope problem before the telehealth question arises.
• PDMP check. The prescriber or a designee must consult E-FORCSE, Florida's PDMP, before prescribing a controlled substance for a patient age 16 or older, with narrow exceptions (Fla. Stat. § 893.055(8)). See PDMP checks for telehealth prescribers.
• Electronic prescribing. A practitioner who keeps electronic health records, or prescribes as part of a practice that does, may only transmit prescriptions electronically, subject to listed exceptions and waivers (Fla. Stat. § 456.42(3)).

Do out-of-state telehealth registrants follow the same rules?

Yes, and they start with less room. Section 456.47(4)(a) lets a registered out-of-state provider treat Florida patients "within the applicable scope of practice established by Florida law or rule," so a registered NP or PA from another state inherits Florida's seven-day Schedule II cap. Registrants cannot open a Florida office or see Florida patients in person (§ 456.47(4)(f)), which closes off the in-person route a Florida-licensed clinician could use to move a patient outside the telehealth statute. Registration itself is covered in Florida's out-of-state telehealth registration.

How does Florida's rule interact with DEA?

Both apply; the stricter one wins. Through December 31, 2026, DEA's temporary rule (90 FR 61301) lets registered practitioners prescribe Schedule II by real-time telemedicine without a prior in-person evaluation. Florida narrows that to the four exceptions. From January 1, 2027, if the Ryan Haight Act's in-person requirement returns, a Florida psychiatric patient will need either an in-person evaluation by the prescriber or another federal pathway, even though Florida law itself would allow the telehealth prescription. DEA's special registration proposal (90 FR 6541) would, if finalized as proposed, add its own Schedule II limits. See what changes on January 1, 2027.

What if the provider saw the patient in person first?

Section 456.47 limits using telehealth to prescribe. A Schedule II prescription issued at, or as the continuation of, an in-person visit raises a different question than one issued by video to a patient never seen. How a later video refill is characterized is for Florida counsel. Federal law is clearer: once the prescriber has done an in-person evaluation, DEA says the Ryan Haight Act's remote prescribing limits no longer apply to that relationship.

What should a practice with Florida patients check?

• Every Florida Schedule II patient is tagged with the exception relied on, and psychiatric-disorder cases have the diagnosis documented.
• No Schedule II opioids for chronic pain by telehealth.
• NP and PA Schedule II prescriptions are capped at seven days unless the prescriber is a psychiatric nurse prescribing psychiatric medication.
• E-FORCSE checks are logged before every controlled substance prescription.
• Every prescriber has a DEA registration for Florida.

The Florida page in our telehealth law index has the statute citations. Our DEA Telemedicine Readiness engagement ($1,450) builds this checklist into your prescribing workflow, and a State Expansion Pack ($595 per state) covers a single new state such as Florida. All of it is research for your counsel, not legal advice.